American College of Cardiology 2022: Four Trials Concerning Lipid Management

Erin D. Michos, MD, MHS


April 08, 2022

Reporting on the whirl of data emerging from the American College of Cardiology 2022 Scientific Session, Erin D. Michos, MD, addresses the results of four key trials: APOLLO, a phase 1 study aimed at assessing the efficacy of the siRNA agent SLN360 at lowering lipoprotein (a) levels; PACMAN-AMI, investigating the effect of alirocumab on coronary plaque composition; SuperWIN, an innovative study testing whether nutritional education can lead to improvements in diet; and TRANSLATE-TIMI 70, examining the impact of the antisense oligonucleotide vupanorsen on ANGPTL3, a lipoprotein lipase inhibitor.

All four studies, Dr Michos notes, displayed varying degrees of positive results, with the outcomes of APOLLO in particular showing promise in the realm of future therapeutics for lipid management.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.